Examining Genetic Associations with Hepatic Steatosis in Mexican-origin Adults

Overview

Journal Ann Hepatol

Specialty Gastroenterology

Date 2023 Jun 4

PMID 37271481

Authors

Mario Jesus Trejo

Kristin E Morrill

Yann C Klimentidis

David O Garcia

Affiliations

Soon will be listed here.

Abstract

Introduction And Objectives: Various studies have identified single-nucleotide polymorphisms (SNPs) associated with nonalcoholic fatty liver disease (NAFLD) and related traits, including ones located in or near the LYPLAL1, GCKR, PPP1R3B, TM6SF2, MBOAT7, and PNPLA3 genes. However, these SNPs were identified primarily in populations of European ancestry. This study examined the associations of these previously identified SNPs with hepatic steatosis in a sample of Mexican-origin adults living in Southern Arizona.

Materials And Methods: A total of 307 Mexican-origin adults between the ages of 18 and 64 with a body mass index (BMI) of 25 kg/m2 or higher were genotyped at the following SNPs: rs12137855 (LYPLAL1), rs1260326 (GCKR), rs4240624 (PPP1R3B), rs58542926 (TM6SF2), rs641738 (MBOAT7), and rs738409 (PNPLA3). Hepatic steatosis was assessed by transient elastography (FibroScan®) with controlled attenuation parameter. Regression models examined the association between each of the six SNPs and hepatic steatosis. BMI was examined as a potential modifier of the genetic associations.

Results: Participants were, on average, 45 years old and mostly female (63%) with an overall mean hepatic steatosis of 288.1 dB/m. Models showed no associations between LYPLAL1, GCKR, PPP1R3B, TM6SF2, or MBOAT7 and hepatic steatosis. Only PNPLA3 was statistically significantly associated with hepatic steatosis in both unadjusted and adjusted models (p<0.01). There was no effect modification observed with BMI.

Conclusions: SNPs associated with NAFLD in populations of European descent did not strongly contribute to hepatic steatosis in individuals of Mexican-origin, except for rs738409 (PNPLA3). Further efforts are necessary to explore additional SNPs that may be associated with NAFLD in this high-risk population.

Citing Articles

Genetic Predictors of Comorbid Course of COVID-19 and MAFLD: A Comprehensive Analysis.

Buchynskyi M, Oksenych V, Kamyshna I, Vari S, Kamyshnyi A Viruses. 2023; 15(8).

PMID: 37632067 PMC: 10459448. DOI: 10.3390/v15081724.

References

Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, DErasmo L, Polimeni L . Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Sci Rep. 2018; 8(1):3702. PMC: 5829219. DOI: 10.1038/s41598-018-21939-0. View

Wang X, Liu Z, Wang K, Wang Z, Sun X, Zhong L . Additive Effects of the Risk Alleles of PNPLA3 and TM6SF2 on Non-alcoholic Fatty Liver Disease (NAFLD) in a Chinese Population. Front Genet. 2016; 7:140. PMC: 4969299. DOI: 10.3389/fgene.2016.00140. View

Eslam M, Valenti L, Romeo S . Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2017; 68(2):268-279. DOI: 10.1016/j.jhep.2017.09.003. View

Speliotes E, Yerges-Armstrong L, Wu J, Hernaez R, Kim L, Palmer C . Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 2011; 7(3):e1001324. PMC: 3053321. DOI: 10.1371/journal.pgen.1001324. View

Miller K, Sauer A, Ortiz A, Fedewa S, Pinheiro P, Tortolero-Luna G . Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018; 68(6):425-445. DOI: 10.3322/caac.21494. View

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

Manning A, Goustin A, Kleinbrink E, Thepsuwan P, Cai J, Ju D . A Long Non-coding RNA, , Is an Effector Transcript at the Chromosome 8p23.1- Metabolic Traits and Type 2 Diabetes Risk Locus. Front Genet. 2020; 11:615. PMC: 7367044. DOI: 10.3389/fgene.2020.00615. View

Chalasani N, Younossi Z, Lavine J, Charlton M, Cusi K, Rinella M . The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017; 67(1):328-357. DOI: 10.1002/hep.29367. View

Flores Y, Velazquez-Cruz R, Ramirez P, Banuelos M, Zhang Z, Yee Jr H . Association between PNPLA3 (rs738409), LYPLAL1 (rs12137855), PPP1R3B (rs4240624), GCKR (rs780094), and elevated transaminase levels in overweight/obese Mexican adults. Mol Biol Rep. 2016; 43(12):1359-1369. PMC: 5106313. DOI: 10.1007/s11033-016-4058-z. View

10.

Lazo M, Hernaez R, Eberhardt M, Bonekamp S, Kamel I, Guallar E . Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 178(1):38-45. PMC: 3698993. DOI: 10.1093/aje/kws448. View

11.

Lazo M, Bilal U, Perez-Escamilla R . Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin. Curr Diab Rep. 2015; 15(12):116. DOI: 10.1007/s11892-015-0674-6. View

12.

Edelman D, Kalia H, Delio M, Alani M, Krishnamurthy K, Abd M . Genetic analysis of nonalcoholic fatty liver disease within a Caribbean-Hispanic population. Mol Genet Genomic Med. 2016; 3(6):558-69. PMC: 4694126. DOI: 10.1002/mgg3.168. View

13.

Trepo E, Romeo S, Zucman-Rossi J, Nahon P . PNPLA3 gene in liver diseases. J Hepatol. 2016; 65(2):399-412. DOI: 10.1016/j.jhep.2016.03.011. View

14.

Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, Pennacchio L . Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008; 40(12):1461-5. PMC: 2597056. DOI: 10.1038/ng.257. View

15.

Luo F, Oldoni F, Das A . TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. Hepatol Commun. 2021; 6(3):448-460. PMC: 8870032. DOI: 10.1002/hep4.1822. View

16.

Lin Y, Chang P, Chang M, Ni Y . Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr. 2014; 99(4):869-74. DOI: 10.3945/ajcn.113.079749. View

17.

Karanjia R, Crossey M, Cox I, Fye H, Njie R, Goldin R . Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol. 2016; 22(45):9880-9897. PMC: 5143756. DOI: 10.3748/wjg.v22.i45.9880. View

18.

Krawczyk M, Rau M, Schattenberg J, Bantel H, Pathil A, Demir M . Combined effects of the PNPLA3 rs738409, TM6SF2 rs58542926, and MBOAT7 rs641738 variants on NAFLD severity: a multicenter biopsy-based study. J Lipid Res. 2016; 58(1):247-255. PMC: 5234727. DOI: 10.1194/jlr.P067454. View

19.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

20.

Hernaez R, McLean J, Lazo M, Brancati F, Hirschhorn J, Borecki I . Association between variants in or near PNPLA3, GCKR, and PPP1R3B with ultrasound-defined steatosis based on data from the third National Health and Nutrition Examination Survey. Clin Gastroenterol Hepatol. 2013; 11(9):1183-1190.e2. PMC: 4197011. DOI: 10.1016/j.cgh.2013.02.011. View